Abstract |
Vindesine, a semisynthetic derivative of vinblastine sulfate, was tested for antitumor activity and clinical toxicity in 36 children. The drug was administered to the initial 13 patients entered into the study a 2 mg/m2/day for five days by IV bolus. Because of severe neurotoxicity and life-threatening gastrointestinal toxicity, the regimen in 23 patients was modified to 4mg/m2 IV infusion over four hours, weekly. This latter regimen was well tolerated, with acceptable gastrointestinal, hematological, and neurotoxicity. One child with acute lymphocytic leukemia resistant to vincristine had a transient M1 remission bone marrow. Improvement or stable disease was noted in one patient each with Ewing's sarcoma, neuroblastoma, and Hodgkin's disease.
|
Authors | L J Ettinger, M Brecher, M Coleman, W A Smithson, R Patterson, E C Russell, T Necheles, B Jones, T Ohnuma |
Journal | Medical and pediatric oncology
(Med Pediatr Oncol)
Vol. 10
Issue 1
Pg. 35-43
( 1982)
ISSN: 0098-1532 [Print] United States |
PMID | 7038420
(Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Vinblastine
- Vindesine
|
Topics |
- Adolescent
- Anemia
(chemically induced)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Clinical Trials as Topic
- Drug Administration Schedule
- Drug Evaluation
- Gastrointestinal Diseases
(chemically induced)
- Humans
- Infant
- Leukemia, Lymphoid
(drug therapy)
- Leukopenia
(chemically induced)
- Vinblastine
(adverse effects, analogs & derivatives, therapeutic use)
- Vindesine
|